CompBrief BY VELARION

Companies Aveo Pharmaceuticals, Inc

Aveo Pharmaceuticals CEO salary & total pay, FY2021: $2.9M

Aveo Pharmaceuticals (AVEO) CEO salary, fiscal 2021: Michael Bailey was paid a salary of $589,959 and $2,943,905 in total compensation. Free brief. Every figure links to the company’s own filing.

Aveo Pharmaceuticals, Inc no longer files a proxy statement; its last pay data is FY2021.

All products and prices

Michael Bailey's complete compensation dossier

A PDF and a CSV sent to your email: Michael Bailey's pay in every fiscal year Aveo Pharmaceuticals, Inc reported it, line by line, with Michael Bailey's equity grants and Aveo Pharmaceuticals, Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$2,943,905CEO Michael Bailey · source
Say-on-pay support85.18%Latest vote · source
CEO vs. named peers40th pct.Of 31 peer CEOs
CEO pay ratio11:1To the median employee · source

CEO pay, last three years

  • $1,599,858FY2020
  • $2,943,905FY2021

CEO total pay was $2,943,905 in fiscal 2021, up from $1,599,858 in fiscal 2020.

FY2021: salary $589,959 · bonus $0 · stock awards $0 · option awards $1,976,786

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Aveo Pharmaceuticals, Inc in fiscal 2021?
As disclosed, Michael Bailey (Chief Executive Officer) was the highest-paid executive at Aveo Pharmaceuticals, Inc in fiscal 2021, with total compensation of $2,943,905.
How does Aveo Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Bailey's total compensation ranked at the 40th percentile of Aveo Pharmaceuticals, Inc's disclosed peer group.
What is Aveo Pharmaceuticals, Inc's CEO-to-median employee pay ratio?
As disclosed, Aveo Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 11:1.
How did shareholders vote on Aveo Pharmaceuticals, Inc's executive compensation?
As disclosed, 85.18% of shareholders supported Aveo Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.
How much does Aveo Pharmaceuticals, Inc spend in total on board compensation for fiscal 2021?
As disclosed, Aveo Pharmaceuticals, Inc reported total board compensation of $362,287 for fiscal 2021.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Michael Bailey$589,959$0$0$1,976,786$308,254$0$68,906$2,943,905
Chief Executive Officer
Michael Needle416,40900718,57000272,2971,407,276
Chief Medical Officer
Michael Ferraresso370,36910,0000718,570145,18505,9971,250,121
Chief Commercial Officer
Erick Lucera374,00000718,570142,12008,0941,242,784
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2021 totalFY2020 totalFY2019 totalΔ FY2020→2021
Michael Bailey$2,943,905$1,599,858—↑ +1,344,047
Michael Needle1,407,276830,071—↑ +577,205
Michael Ferraresso1,250,121707,187—↑ +542,934
Erick Lucera1,242,784780,541—↑ +462,243

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our approach to executive compensation is guided by principles of holding executive officers accountable for long-term results, rewarding consistent strong execution, and establishing a clear connection between rewards and performance. We seek to achieve financial strength by linking compensation to performance goals and using equity as a key component of compensation.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2021

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael FerraressoOPTION2021-02-05——100,000—$718,570
Michael NeedleOPTION2021-02-05——100,000—718,570
Michael BaileyOPTION2021-02-05——275,100—1,976,786
Erick LuceraOPTION2021-02-05——100,000—718,570

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Ferraresso$0$0$718,5700.0%
Michael Needle00718,5700.0%
Michael Bailey001,976,7860.0%
Erick Lucera00718,5700.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2021

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Erick LuceraOption20,83379,1679.12—
Erick LuceraOption23,95226,0486.7—
Michael BaileyOption57,312217,7889.12—
Michael BaileyOption55,46265,5625.6—
Michael BaileyOption85,00034,9996.2—
Michael BaileyOption95,8324,16730.8—
Michael BaileyOption75,366—6—
Michael BaileyOption46,000—10.8—
Michael BaileyOption90,000—8.4—
Michael BaileyOption16,750—15.7—
Michael BaileyOption7,499—17.7—
Michael BaileyOption11,999—25.1—
Michael BaileyOption3,249—77.2—
Michael BaileyOption3,100—131.8—
Michael FerraressoOption20,83379,1679.12—
Michael FerraressoOption19,47123,0285.6—
Michael FerraressoOption24,83610,2286.2—
Michael FerraressoOption3,59315630.8—
Michael FerraressoOption20,000—28.3—
Michael NeedleOption18,750—9.12—
Michael NeedleOption13,116—5.6—
Michael NeedleOption13,749—6.2—
Michael NeedleOption21,092—30.8—
Michael NeedleOption28,000—6—
Michael NeedleOption18,400—10.8—
Michael NeedleOption50,000—10.7—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Kenneth BateIndependent · Board Chair · Audit (Chair) · Nominating and Governance$88,379—$70,355——$158,734
Corinne EpperlyIndependent · Compensation · Nominating and Governance48,888—99,360——148,248
Kevin CullenIndependent · Audit · Compensation36,663—98,935——135,598
Anthony EvninIndependent · Nominating and Governance (Chair) · Audit57,258—70,355——127,613
Scarlett SpringIndependent · Audit · Compensation (Chair)56,484—70,355——126,839
Gregory MayesIndependent · Compensation · Nominating and Governance50,250—70,355——120,605
Robert YoungIndependent · Not standing for re-election · Departed during FY24,365—0——24,365

Board fee structure and ownership guideline

Annual cash retainer$40,500
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)16,000 / 12,000 / 8,000
Stock ownership guideline—

Total cost of the board

ComponentFY2021
Cash retainers and fees$362,287
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$362,287

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Aveo Pharmaceuticals as a peer

Companies that benchmark against AVEO

No companies currently name AVEO as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Disclosed peer group — fiscal year 2021

The peer group as the company's own proxy names it, the “2022 peer group” — the reference set behind the percentile above.

Peer reciprocity

The companies Aveo Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eagle Pharmaceuticals, Inc.2022Scott Tarriff$848,940$9,011,197$0$636,705$10,520,577
2Geron Corporation2025Harout Semerjian321,53809,695,400203,00010,221,755
3Syndax Pharmaceuticals, Inc.2025Michael Metzger754,3002,021,9653,454,360848,5887,089,213
4Akebia Therapeutics, Inc.2025John Butler864,0102,164,3382,024,798580,9735,652,339
5Xeris Biopharma Holdings, Inc.2025John Shannon742,3342,848,000838,615607,9715,042,584
6Aldeyra Therapeutics, Inc.2025Todd Brady700,00003,801,379189,0004,704,179
7Rigel Pharmaceuticals, Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
8Intercept Pharmaceuticals, Inc.2022Jerome Durso714,8132,547,438535,540634,5524,455,463
9UroGen Pharma, Ltd.2025Elizabeth Barrett855,5902,122,2110516,2634,310,624
10Corbus Pharmaceuticals Holdings, Inc.2025Yuval Cohen646,566666,6992,039,29403,750,125
11Esperion Therapeutics, Inc.2025Sheldon Koenig770,8331,260,000847,929639,3753,535,512
12Aquestive Therapeutics, Inc.2025Daniel Barber659,8851,547,342877,200409,1323,493,559
13G1 Therapeutics, Inc.2023John Bailey794,9761,392,022666,209387,5513,250,658
14Puma Biotechnology, Inc.2025Alan Auerbach931,333551,549535,5131,027,3073,062,337
15Aveo Pharmaceuticals, Inc2021Michael Bailey589,95901,976,786308,2542,943,905
16X4 Pharmaceuticals, Inc.2025Paula Ragan420,1701,081,575002,640,569
17Oncocyte Corporation2025Joshua Riggs472,293599,9991,332,00002,594,786
18Isoray, Inc.2025Johan Spoor680,00001,302,692408,0002,404,692
19Verastem, Inc.2025Daniel Paterson674,0001,161,6610489,3242,349,975
20Karyopharm Therapeutics Inc.2025Richard Paulson770,000838,996241,544350,3502,320,902
21Actinium Pharmaceuticals, Inc.2025Sandesh Seth762,3200001,187,320
22MEI Pharma, Inc.2025David Urso53,528000934,046
23Aytu BioPharma, Inc.2026Joshua Disbrow608,15442,7500177,000844,854
—Clovis Oncology, Inc.——————not in coverage universe
—Aprea Therapeutics, Inc.——————not in coverage universe
—Strongbridge Biopharma plc——————not in coverage universe
—Calithera Biosciences, Inc.——————not in coverage universe
—Idera Pharmaceuticals, Inc.——————not in coverage universe
—Casi Pharmaceuticals, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Aveo Pharmaceuticals, Incnot disclosedOption 100not disclosedAon
Actinium Pharmaceuticals, Inc.not disclosednot disclosednot disclosedStreeterWyatt Analytics LLC
Akebia Therapeutics, Inc.90%Options 50 · RSU 25 · MSU 25NoPearl Meyer
Aldeyra Therapeutics, Inc.not disclosedOption 100not disclosedPearl Meyer & Partners, LLC
Aprea Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Aquestive Therapeutics, Inc.not disclosedOptions 42 · PSU 30 · RSU 28NoAon
Aytu BioPharma, Inc.50%not disclosednot disclosedAlvarez and Marsal Holdings, LLC
Calithera Biosciences, Inc.not disclosednot disclosednot disclosednot disclosed
Casi Pharmaceuticals, Inc.not disclosednot disclosednot disclosednot disclosed
Clovis Oncology, Inc.not disclosednot disclosednot disclosednot disclosed
Corbus Pharmaceuticals Holdings, Inc.not disclosednot disclosednot disclosedCompensia, Inc.
Eagle Pharmaceuticals, Inc.75%PSU 75 · RSU 25Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR)Compensia
Esperion Therapeutics, Inc.110%not disclosednot disclosednot disclosed
G1 Therapeutics, Inc.not disclosednot disclosednot disclosedRadford, Aon’s Human Capital Solutions Practice
Geron Corporation90%Options 75 · RSU 25not disclosedAon
Idera Pharmaceuticals, Inc.not disclosednot disclosednot disclosednot disclosed
Intercept Pharmaceuticals, Inc.not disclosednot disclosednot disclosedAon plc's Rewards Solution practice (Radford)
Isoray, Inc.100%Options 100not disclosedAon
Karyopharm Therapeutics Inc.90%not disclosedYes — Relative TSRAlpine, WTW
MEI Pharma, Inc.not disclosednot disclosednot disclosednot disclosed
Oncocyte Corporationnot disclosednot disclosednot disclosedFrederic W. Cook & Co., Inc.
Puma Biotechnology, Inc.169.7%Options 50 · RSU 50not disclosedCompensia
Rigel Pharmaceuticals, Inc.124%Options 75 · RSU 25NoPearl Meyer
Strongbridge Biopharma plcnot disclosednot disclosednot disclosednot disclosed
Syndax Pharmaceuticals, Inc.150%Options 34 · PSU 33 · RSU 33Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRsAon
UroGen Pharma, Ltd.80%RSU 50 · PSU 50NoCompensia, Inc.
Verastem, Inc.not disclosednot disclosednot disclosedPearl Meyer
X4 Pharmaceuticals, Inc.not disclosednot disclosednot disclosednot disclosed
Xeris Biopharma Holdings, Inc.125%not disclosednot disclosedAon Consulting, Inc.

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20202020-06-104,480,153779,43883,33185.18%Passed
20192019-06-1244,043,40715,566,550874,33073.89%Passed
20182018-06-1848,704,579783,037282,56698.42%Passed
20172017-06-2151,716,387857,651123,84998.37%Passed
20162016-05-2618,201,331496,243145,67397.35%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20202020-06-1085.18%a
20192019-06-1273.89%b
20182018-06-1898.42%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)11 : 1
CEO total compensation$2,943,905
Median employee compensation$278,596
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2021 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Erick LuceraChief Financial Officer2023-01-19D218,800——Derivative, Class A CommonForm 4 ↗
Erick LuceraChief Financial Officer2023-01-19D100,000——Derivative, Class A CommonForm 4 ↗
Erick LuceraChief Financial Officer2023-01-19D50,000——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D625,192——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D275,100——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D35,302——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D93,500——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D16,750——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D99,999——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D75,366——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D46,000——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D90,000——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D7,499——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D11,999——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D3,249——Derivative, Class A CommonForm 4 ↗
Michael BaileyDirector2023-01-19D333,167154,997,505CommonForm 4 ↗
Mayes, Gregory T.Director2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Mayes, Gregory T.Director2023-01-19D12,500——Derivative, Class A CommonForm 4 ↗
Mayes, Gregory T.Director2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Mayes, Gregory T.Director2023-01-19D10,000——Derivative, Class A CommonForm 4 ↗
Scarlett SpringDirector2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Scarlett SpringDirector2023-01-19D12,500——Derivative, Class A CommonForm 4 ↗
Scarlett SpringDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Scarlett SpringDirector2023-01-19D10,000——Derivative, Class A CommonForm 4 ↗
Kevin CullenDirector2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Kevin CullenDirector2023-01-19D25,000——Derivative, Class A CommonForm 4 ↗
Corinne EpperlyDirector2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Corinne EpperlyDirector2023-01-19D15,000——Derivative, Class A CommonForm 4 ↗
Corinne EpperlyDirector2023-01-19D10,000——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D220,000——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D100,000——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D42,499——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D35,064——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D3,749——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D20,000——Derivative, Class A CommonForm 4 ↗
Michael FerraressoChief Commercial Officer2023-01-19D16,34515245,175CommonForm 4 ↗
Jebediah LedellChief Operating Officer2023-01-19D27,702——Derivative, Class A CommonForm 4 ↗
Jebediah LedellChief Operating Officer2023-01-19D170,000——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D12,500——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D7,785——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D6,402——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D2,000——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D2,515——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D1,250——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D1,250——Derivative, Class A CommonForm 4 ↗
Anthony EvninDirector2023-01-19D41,84115627,615CommonForm 4 ↗
Kenneth BateDirector2023-01-19D22,500——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D12,500——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D4,000——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D7,785——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D6,402——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D2,000——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D2,515——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D1,250——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D1,250——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2023-01-19D375155,625CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (108 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Michael Bailey. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 2,943,905. View filing ↗
  • Section 01, Michael Needle. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,407,276. View filing ↗
  • Section 01, Michael Ferraresso. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,250,121. View filing ↗
  • Section 01, Erick Lucera. DEF 14A, filed 2022-04-26. Section “Summary Compensation Table” · page 47. As printed: 1,242,784. View filing ↗
  • Section 03, Michael Ferraresso OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Needle OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Bailey OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
  • Section 03, Erick Lucera OPTION. DEF 14A, filed 2022-04-26. Section “Grants of Plan-Based Awards for the Year Ended December 31, 202” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2022-04-26. Section “CEO Pay Ratio”. As printed: 11 : 1. View filing ↗
  • Section 08, Kenneth Bate. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 158,734. View filing ↗
  • Section 08, Corinne Epperly. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 148,248. View filing ↗
  • Section 08, Kevin Cullen. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 135,598. View filing ↗
  • Section 08, Anthony Evnin. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 127,613. View filing ↗
  • Section 08, Scarlett Spring. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 126,839. View filing ↗
  • Section 08, Gregory Mayes. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 120,605. View filing ↗
  • Section 08, Robert Young. DEF 14A, filed 2022-04-26. Section “Director Compensation”. As printed: 24,365. View filing ↗
  • Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Erick Lucera 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bailey 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mayes, Gregory T. 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scarlett Spring 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin Cullen 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin Cullen 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Corinne Epperly 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Ferraresso 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jebediah Ledell 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jebediah Ledell 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Evnin 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kenneth Bate 2023-01-19. Form 4, filed 2023-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2020 vote. Form 8-K, filed 2020-06-10. Item 5.07 · say-on-pay result. As reported: 85.18% (votes for as printed: 4,480,153). View filing ↗
  • Section 06, 2019 vote. Form 8-K, filed 2019-06-13. Item 5.07 · say-on-pay result. As reported: 73.89% (votes for as printed: 44,043,407). View filing ↗
  • Section 06, 2018 vote. Form 8-K, filed 2018-06-21. Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 48,704,579). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 362,287 + equity 0 + all other 0 = 362,287, summed across the director compensation table rows.
  • Eagle Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Eagle Pharmaceuticals, Inc.'s own proxy. As printed: 10,520,577. View filing ↗
  • Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
  • Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
  • Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
  • Xeris Biopharma Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Xeris Biopharma Holdings, Inc.'s own proxy. As printed: 5,042,584. View filing ↗
  • Aldeyra Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Aldeyra Therapeutics, Inc.'s own proxy. As printed: 4,704,179. View filing ↗
  • Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
  • Intercept Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Intercept Pharmaceuticals, Inc.'s own proxy. As printed: 4,455,463. View filing ↗
  • UroGen Pharma, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in UroGen Pharma, Ltd.'s own proxy. As printed: 4,310,624. View filing ↗
  • Corbus Pharmaceuticals Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Corbus Pharmaceuticals Holdings, Inc.'s own proxy. As printed: 3,750,125. View filing ↗
  • Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
  • Aquestive Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Aquestive Therapeutics, Inc.'s own proxy. As printed: 3,493,559. View filing ↗
  • G1 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in G1 Therapeutics, Inc.'s own proxy. As printed: 3,250,658. View filing ↗
  • Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
  • Aveo Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2022-04-26. CEO total compensation as printed in Aveo Pharmaceuticals, Inc's own proxy. As printed: 2,943,905. View filing ↗
  • X4 Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in X4 Pharmaceuticals, Inc.'s own proxy. As printed: 2,640,569. View filing ↗
  • Oncocyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Oncocyte Corporation's own proxy. As printed: 2,594,786. View filing ↗
  • Isoray, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Isoray, Inc.'s own proxy. As printed: 2,404,692. View filing ↗
  • Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
  • Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
  • Actinium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗
  • MEI Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-30. CEO total compensation as printed in MEI Pharma, Inc.'s own proxy. As printed: 934,046. View filing ↗
  • Aytu BioPharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-22. CEO total compensation as printed in Aytu BioPharma, Inc.'s own proxy. As printed: 844,854. View filing ↗
  • Section 10a, G1 Therapeutics, Inc. reciprocity. DEF 14A. G1 Therapeutics, Inc. names Aveo Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗